CD8A and neoplasm: By engineering CD8+ T cells to express TCRs derived from patients’ tumor–specific cytotoxic T cells (CTLs), they can be converted from a population of polyclonal CD8+ T cells to CTL of monoclonal TCR specificity [1, 2].